In last trading session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) saw 1.02 million shares changing hands with its beta currently measuring 0.38. Company’s recent per share price level of $2.79 trading at $0.07 or 2.57% at ring of the bell on the day assigns it a market valuation of $443.61M. That closing price of MREO’s stock is at a discount of -79.93% from its 52-week high price of $5.02 and is indicating a premium of 43.37% from its 52-week low price of $1.58.
For Mereo Biopharma Group Plc ADR (MREO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Upright in the green during last session for gaining 2.57%, in the last five days MREO remained trading in the red while hitting it’s week-highest on Friday, 06/20/25 when the stock touched $2.79 price level, adding 5.1% to its value on the day. Mereo Biopharma Group Plc ADR’s shares saw a change of -29.90% in year-to-date performance and have moved -0.36% in past 5-day. Mereo Biopharma Group Plc ADR (NASDAQ:MREO) showed a performance of 24.55% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7.5 to the stock, which implies a rise of 62.8% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -43.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -43.37% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.82% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 58.86% while estimates for its earnings growth in next 5 years are of 25.31%.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
RUBRIC CAPITAL MANAGEMENT LP is the top institutional holder at MREO for having 15.31 million shares of worth $55.11 million. And as of 2024-06-30, it was holding 2.1506 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.79 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6566 of outstanding shares, having a total worth of $42.45 million.
